Cagent Vascular closed an oversubscribed $41 million Series D to advance its dual-modality intravascular lithotripsy platform toward coronary commercialization and further clinical testing. The financing will fund the global REMODEL II trial, the commercial launch of the SONIC IVL system, and development of a coronary artery iteration. Cagent said it has completed successful first human-use cases in Uzbekistan for REMODEL I (NCT07575568) and positioned its SONIC system as an IVL approach that transmits ultrasonic acoustic waves directly into calcified plaque. The company described its adjustable energy delivery and dual-modality serration remodeling plus lithotripsy as addressing complex lesion morphologies versus conventional IVL-only platforms.